CA2874092A1 - Method for treating non-small cell lung cancer - Google Patents
Method for treating non-small cell lung cancer Download PDFInfo
- Publication number
- CA2874092A1 CA2874092A1 CA2874092A CA2874092A CA2874092A1 CA 2874092 A1 CA2874092 A1 CA 2874092A1 CA 2874092 A CA2874092 A CA 2874092A CA 2874092 A CA2874092 A CA 2874092A CA 2874092 A1 CA2874092 A1 CA 2874092A1
- Authority
- CA
- Canada
- Prior art keywords
- human patient
- clusterin
- lung cancer
- nucleotides
- small cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 343
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 341
- 238000000034 method Methods 0.000 title claims abstract description 63
- 241000282414 Homo sapiens Species 0.000 claims abstract description 280
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 208
- 239000002773 nucleotide Substances 0.000 claims abstract description 203
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 203
- 238000002512 chemotherapy Methods 0.000 claims abstract description 158
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 116
- 229960003668 docetaxel Drugs 0.000 claims abstract description 116
- 230000001394 metastastic effect Effects 0.000 claims abstract description 78
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 78
- 238000012986 modification Methods 0.000 claims abstract description 76
- 230000004048 modification Effects 0.000 claims abstract description 76
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical class CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims abstract description 67
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 238000011282 treatment Methods 0.000 claims description 234
- 102000003780 Clusterin Human genes 0.000 claims description 146
- 108090000197 Clusterin Proteins 0.000 claims description 146
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 143
- 210000002966 serum Anatomy 0.000 claims description 82
- 229910052697 platinum Inorganic materials 0.000 claims description 71
- 230000004083 survival effect Effects 0.000 claims description 71
- 239000002246 antineoplastic agent Substances 0.000 claims description 70
- 229940127089 cytotoxic agent Drugs 0.000 claims description 70
- 239000003814 drug Substances 0.000 claims description 62
- 238000002560 therapeutic procedure Methods 0.000 claims description 38
- 230000000977 initiatory effect Effects 0.000 claims description 32
- 208000020816 lung neoplasm Diseases 0.000 claims description 28
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 27
- 201000005202 lung cancer Diseases 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 22
- 230000008901 benefit Effects 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 230000003442 weekly effect Effects 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 15
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 14
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 201000009546 lung large cell carcinoma Diseases 0.000 claims description 11
- 208000002151 Pleural effusion Diseases 0.000 claims description 10
- 229910001415 sodium ion Inorganic materials 0.000 claims description 10
- 206010008479 Chest Pain Diseases 0.000 claims description 9
- 208000000059 Dyspnea Diseases 0.000 claims description 9
- 206010013975 Dyspnoeas Diseases 0.000 claims description 9
- 230000002035 prolonged effect Effects 0.000 claims description 8
- 208000000616 Hemoptysis Diseases 0.000 claims description 7
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 7
- 208000005333 pulmonary edema Diseases 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000000737 periodic effect Effects 0.000 claims description 3
- RCFZILUHCNXXFY-DEDWCYLFSA-N custirsen Chemical compound N1([C@@H]2O[C@H](COP(O)(=S)O[C@H]3[C@H]([C@@H](O[C@@H]3COP(S)(=O)O[C@H]3[C@H]([C@@H](O[C@@H]3COP(O)(=S)O[C@H]3[C@H]([C@@H](O[C@@H]3COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C4=NC=NC(N)=C4N=C3)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C(N=C(N)C=C3)=O)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C(NC(=O)C(C)=C3)=O)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C(NC(=O)C(C)=C3)=O)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C(N=C(N)C=C3)=O)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C(NC(=O)C(C)=C3)=O)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C4=C(C(NC(N)=N4)=O)N=C3)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C4=NC=NC(N)=C4N=C3)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C4=C(C(NC(N)=N4)=O)N=C3)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C4=NC=NC(N)=C4N=C3)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C(N=C(N)C=C3)=O)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C4=C(C(NC(N)=N4)=O)N=C3)COP(O)(=S)O[C@@H]3[C@H](O[C@H](C3)N3C4=NC=NC(N)=C4N=C3)COP(O)(=S)O[C@H]3[C@H]([C@@H](O[C@@H]3COP(O)(=S)O[C@H]3[C@H]([C@@H](O[C@@H]3COP(O)(=S)O[C@H]3[C@H]([C@@H](O[C@@H]3COP(O)(=S)O[C@H]3[C@H]([C@@H](O[C@@H]3CO)N3C(N=C(N)C(C)=C3)=O)OCCOC)N3C4=NC=NC(N)=C4N=C3)OCCOC)N3C4=C(C(NC(N)=N4)=O)N=C3)OCCOC)N3C(N=C(N)C(C)=C3)=O)OCCOC)N3C(NC(=O)C(C)=C3)=O)OCCOC)N3C(N=C(N)C(C)=C3)=O)OCCOC)N3C4=NC=NC(N)=C4N=C3)OCCOC)[C@@H](O)[C@H]2OCCOC)C=C(C)C(=O)NC1=O RCFZILUHCNXXFY-DEDWCYLFSA-N 0.000 description 208
- 229950001605 custirsen Drugs 0.000 description 207
- 229960001592 paclitaxel Drugs 0.000 description 164
- 229930012538 Paclitaxel Natural products 0.000 description 159
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 159
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 132
- 229960004562 carboplatin Drugs 0.000 description 130
- 229940123237 Taxane Drugs 0.000 description 83
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 69
- 238000001802 infusion Methods 0.000 description 52
- 206010028980 Neoplasm Diseases 0.000 description 43
- 229940079593 drug Drugs 0.000 description 40
- 238000004458 analytical method Methods 0.000 description 38
- 206010061818 Disease progression Diseases 0.000 description 35
- 201000010099 disease Diseases 0.000 description 34
- 230000005750 disease progression Effects 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 238000011068 loading method Methods 0.000 description 33
- 201000011510 cancer Diseases 0.000 description 28
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 28
- 230000034994 death Effects 0.000 description 24
- 231100000517 death Toxicity 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 24
- 230000001988 toxicity Effects 0.000 description 23
- 231100000419 toxicity Toxicity 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 238000012216 screening Methods 0.000 description 22
- 230000003902 lesion Effects 0.000 description 20
- 230000004044 response Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 238000002595 magnetic resonance imaging Methods 0.000 description 15
- 238000002591 computed tomography Methods 0.000 description 14
- 229940109239 creatinine Drugs 0.000 description 14
- 230000002411 adverse Effects 0.000 description 13
- 238000011518 platinum-based chemotherapy Methods 0.000 description 13
- 238000001959 radiotherapy Methods 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 10
- 239000000074 antisense oligonucleotide Substances 0.000 description 10
- 238000012230 antisense oligonucleotides Methods 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- -1 tesetaxol Chemical compound 0.000 description 9
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 8
- 238000011319 anticancer therapy Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 208000004235 neutropenia Diseases 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 238000009101 premedication Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 231100000402 unacceptable toxicity Toxicity 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 206010029350 Neurotoxicity Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 231100000360 alopecia Toxicity 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 229940102223 injectable solution Drugs 0.000 description 6
- 238000007449 liver function test Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 206010061728 Bone lesion Diseases 0.000 description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 5
- 101800003838 Epidermal growth factor Proteins 0.000 description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 206010044221 Toxic encephalopathy Diseases 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- BKRDNYHYNZJMPG-UHFFFAOYSA-A custirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].COCCOC1C(O)C(COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2CO)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C3=NC=NC(N)=C3N=C2)OCCOC)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C3=NC=NC(N)=C3N=C2)OCCOC)OC1N1C=C(C)C(=O)NC1=O BKRDNYHYNZJMPG-UHFFFAOYSA-A 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940116977 epidermal growth factor Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229960001680 ibuprofen Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000001325 log-rank test Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 231100000228 neurotoxicity Toxicity 0.000 description 5
- 230000007135 neurotoxicity Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 229930014667 baccatin III Natural products 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 229960001573 cabazitaxel Drugs 0.000 description 4
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229960000520 diphenhydramine Drugs 0.000 description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 231100000226 haematotoxicity Toxicity 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229940126602 investigational medicinal product Drugs 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 231100000417 nephrotoxicity Toxicity 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- SXPIMOCRRJUHJY-MNLIZOKASA-N taxcultine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)CCC)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 SXPIMOCRRJUHJY-MNLIZOKASA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000002633 Febrile Neutropenia Diseases 0.000 description 3
- 206010016807 Fluid retention Diseases 0.000 description 3
- 208000009139 Gilbert Disease Diseases 0.000 description 3
- 208000022412 Gilbert syndrome Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010059282 Metastases to central nervous system Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940102213 injectable suspension Drugs 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000003319 supportive effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- ADDGUHVEJPNWQZ-FIKJQGJASA-N 10-Deacetylcephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)/C(=C\C)/C)c1ccccc1 ADDGUHVEJPNWQZ-FIKJQGJASA-N 0.000 description 2
- TYLVGQKNNUHXIP-MHHARFCSSA-N 10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 TYLVGQKNNUHXIP-MHHARFCSSA-N 0.000 description 2
- ADDGUHVEJPNWQZ-GJKIWTKTSA-N 10-deacetyltaxol b Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 ADDGUHVEJPNWQZ-GJKIWTKTSA-N 0.000 description 2
- XGWGQEYABFGJID-UVDBIDMBSA-N 7-Xylosyltaxol C Natural products O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](O)C(=O)[C@]3(C)[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)CCCCC)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 XGWGQEYABFGJID-UVDBIDMBSA-N 0.000 description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 229960005500 DHA-paclitaxel Drugs 0.000 description 2
- 206010067671 Disease complication Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 208000005228 Pericardial Effusion Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- PRSNJXPAQBUJBL-DXKHDLERSA-N [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-(hexanoylamino)-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate Chemical compound CCCCCC(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O[C@@H]4OC[C@@H](O)[C@H](O)[C@H]4O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 PRSNJXPAQBUJBL-DXKHDLERSA-N 0.000 description 2
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 2
- 229940028652 abraxane Drugs 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- IQXIUTMSTALSFW-VJFOLWCZSA-N carboplatin paclitaxel Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 IQXIUTMSTALSFW-VJFOLWCZSA-N 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OUZGCGZMZBOCBH-MNLIZOKASA-N chembl311365 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)CCCCC)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 OUZGCGZMZBOCBH-MNLIZOKASA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229950010897 iproplatin Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 229950005692 larotaxel Drugs 0.000 description 2
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229950008991 lobaplatin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000026721 nail disease Diseases 0.000 description 2
- 229950007221 nedaplatin Drugs 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 2
- 229950001094 ortataxel Drugs 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 229950005566 picoplatin Drugs 0.000 description 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229960005399 satraplatin Drugs 0.000 description 2
- 190014017285 satraplatin Chemical compound 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 2
- BEHTXUBGUDGCNQ-IEAAAIHOSA-N taxol c Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)CCCCC)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 BEHTXUBGUDGCNQ-IEAAAIHOSA-N 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 229950002860 triplatin tetranitrate Drugs 0.000 description 2
- 190014017283 triplatin tetranitrate Chemical compound 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- CWWCQGGNKDBSNT-UHFFFAOYSA-N 2-(2-phenoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=CC=C1 CWWCQGGNKDBSNT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000722985 Fidia Species 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100226013 Mus musculus Ercc1 gene Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241001609918 Pseudocardium sachalinense Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000237545 Spisula solidissima Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- WCIDIJQCEUODDY-UHFFFAOYSA-N chloro(dimethyl)sulfanium Chemical compound C[S+](C)Cl WCIDIJQCEUODDY-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229960005234 diphenoxylate hydrochloride Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 238000011234 economic evaluation Methods 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 238000011375 palliative radiation therapy Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 201000006642 solid adenocarcinoma with mucin production Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649092P | 2012-05-18 | 2012-05-18 | |
| US61/649,092 | 2012-05-18 | ||
| PCT/US2013/041652 WO2013173757A1 (en) | 2012-05-18 | 2013-05-17 | Method for treating non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2874092A1 true CA2874092A1 (en) | 2013-11-21 |
Family
ID=49581824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2874092A Abandoned CA2874092A1 (en) | 2012-05-18 | 2013-05-17 | Method for treating non-small cell lung cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20130310440A1 (enExample) |
| EP (1) | EP2849761A1 (enExample) |
| JP (1) | JP2015522542A (enExample) |
| KR (1) | KR20150024843A (enExample) |
| CN (1) | CN104684564A (enExample) |
| AR (1) | AR091090A1 (enExample) |
| AU (1) | AU2013262589A1 (enExample) |
| BR (1) | BR112014028787A2 (enExample) |
| CA (1) | CA2874092A1 (enExample) |
| EA (1) | EA201492148A1 (enExample) |
| IL (1) | IL235459A0 (enExample) |
| IN (1) | IN2014DN10390A (enExample) |
| PH (1) | PH12014502569A1 (enExample) |
| SG (1) | SG11201407649RA (enExample) |
| TW (1) | TW201402132A (enExample) |
| UY (1) | UY34812A (enExample) |
| WO (1) | WO2013173757A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144975A0 (en) | 1999-02-26 | 2002-06-30 | Univ British Columbia | A composition containing an antisense oligonucleotide |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| PL3581105T3 (pl) | 2010-05-08 | 2022-11-28 | The Regents Of The University Of California | Urządzenie do wczesnego wykrywania owrzodzenia przez skanowanie uwodnienia podnaskórkowego |
| AU2012228010B2 (en) | 2011-03-15 | 2016-08-25 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer |
| CN104473973B (zh) * | 2014-12-19 | 2015-08-05 | 山东创新药物研发有限公司 | 一株戈氏梭菌驯化株的应用 |
| AU2016250527B2 (en) | 2015-04-24 | 2021-01-14 | Bruin Biometrics, Llc | Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements |
| FI3515296T3 (fi) | 2017-02-03 | 2023-12-21 | Bbi Medical Innovations Llc | Kudoksen elinkelpoisuuden mittaus |
| NZ773584A (en) | 2017-02-03 | 2025-07-25 | Bbi Medical Innovations Llc | Measurement of susceptibility to diabetic foot ulcers |
| CA3042101C (en) | 2017-02-03 | 2024-04-09 | Bruin Biometrics, Llc | Measurement of edema |
| MX2020005138A (es) * | 2017-11-16 | 2020-08-17 | Bruin Biometrics Llc | Tratamiento estrategico de ulceras por presion por el uso de valores humedad subepidermica. |
| US20190211044A1 (en) * | 2018-01-05 | 2019-07-11 | LifeUnit Inc. | Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria |
| GB2584226B (en) | 2018-02-09 | 2022-06-22 | Bruin Biometrics Llc | Detection of tissue damage |
| DK4283799T3 (da) | 2018-10-11 | 2025-04-22 | Bruin Biometrics Llc | Indretning med engangselement |
| US11642075B2 (en) | 2021-02-03 | 2023-05-09 | Bruin Biometrics, Llc | Methods of treating deep and early-stage pressure induced tissue damage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| WO2009155381A1 (en) * | 2008-06-18 | 2009-12-23 | Abbott Laboratories | P/gf-1 companion diagnostic methods and products |
| WO2012156817A2 (en) * | 2011-05-19 | 2012-11-22 | Teva Pharmaceutical Industries Ltd. | Method for treating non-small cell lung cancer |
-
2013
- 2013-05-16 UY UY0001034812A patent/UY34812A/es not_active Application Discontinuation
- 2013-05-17 AU AU2013262589A patent/AU2013262589A1/en not_active Abandoned
- 2013-05-17 CN CN201380030309.9A patent/CN104684564A/zh active Pending
- 2013-05-17 KR KR20147035652A patent/KR20150024843A/ko not_active Withdrawn
- 2013-05-17 CA CA2874092A patent/CA2874092A1/en not_active Abandoned
- 2013-05-17 WO PCT/US2013/041652 patent/WO2013173757A1/en not_active Ceased
- 2013-05-17 US US13/896,737 patent/US20130310440A1/en not_active Abandoned
- 2013-05-17 EP EP13791341.4A patent/EP2849761A1/en not_active Withdrawn
- 2013-05-17 JP JP2015512895A patent/JP2015522542A/ja active Pending
- 2013-05-17 EA EA201492148A patent/EA201492148A1/ru unknown
- 2013-05-17 IN IN10390DEN2014 patent/IN2014DN10390A/en unknown
- 2013-05-17 SG SG11201407649RA patent/SG11201407649RA/en unknown
- 2013-05-17 AR ARP130101729A patent/AR091090A1/es unknown
- 2013-05-17 BR BR112014028787A patent/BR112014028787A2/pt not_active IP Right Cessation
- 2013-05-17 TW TW102117597A patent/TW201402132A/zh unknown
-
2014
- 2014-11-02 IL IL235459A patent/IL235459A0/en unknown
- 2014-11-18 PH PH12014502569A patent/PH12014502569A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104684564A (zh) | 2015-06-03 |
| WO2013173757A1 (en) | 2013-11-21 |
| US20130310440A1 (en) | 2013-11-21 |
| AU2013262589A1 (en) | 2015-01-22 |
| IL235459A0 (en) | 2014-12-31 |
| SG11201407649RA (en) | 2014-12-30 |
| EA201492148A1 (ru) | 2015-04-30 |
| BR112014028787A2 (pt) | 2017-06-27 |
| WO2013173757A8 (en) | 2015-04-30 |
| JP2015522542A (ja) | 2015-08-06 |
| AR091090A1 (es) | 2014-12-30 |
| PH12014502569A1 (en) | 2015-01-21 |
| EP2849761A1 (en) | 2015-03-25 |
| TW201402132A (zh) | 2014-01-16 |
| KR20150024843A (ko) | 2015-03-09 |
| IN2014DN10390A (enExample) | 2015-08-14 |
| UY34812A (es) | 2013-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130310440A1 (en) | Method for treating non-small cell lung cancer | |
| US20130017272A1 (en) | Method for treating non-small cell lung cancer | |
| Rudin et al. | Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer | |
| Gatzemeier et al. | Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer | |
| Marshall et al. | A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors | |
| Reardon et al. | Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma | |
| Tolcher et al. | A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer | |
| Chi et al. | A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer | |
| Diep et al. | Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells | |
| Mani et al. | Phase I clinical and pharmacokinetic study of protein kinase C-α antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer | |
| Talbot et al. | A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non–small cell lung cancer | |
| KR20180050426A (ko) | 치료제의 약물 전달 및 유효성 향상 방법 | |
| KR20140009275A (ko) | 파클리탁셀 및 트라스투주맙-mcc-dm1에 의한 her2-양성 암의 치료 | |
| KR20160143775A (ko) | iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도 | |
| KR20200014298A (ko) | Her2 양성 암의 치료 | |
| WO2012167028A2 (en) | Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition | |
| CN107750165A (zh) | 借助塞里班土单抗的组合治疗 | |
| Dixon et al. | Practical guidance for the use of patisiran in the management of polyneuropathy in hereditary transthyretin-mediated amyloidosis | |
| US20240050449A1 (en) | Use of Acetyltanshinone IIA in Preparation of Medicament for Treating Lung Cancer and Medicament for Treating Lung Cancer | |
| US10849906B2 (en) | Use of Akt2 in diagnosis and treatment of tumor | |
| KR20240083178A (ko) | Kras g12c 돌연변이를 포함하는 암의 치료를 위한 소토라십 및 egfr 항체 | |
| US20140335077A1 (en) | Compositions and Methods for the Treatment of Cancer Using IGF-IR Antagonists and MAPK/ERK Inhibitors | |
| JP2022028749A (ja) | 腫瘍の診断および治療におけるＡｋｔ２の使用 | |
| US20130261167A1 (en) | ANCCA as a Diagnostic Biomarker and Therapeutic Target for Breast Cancers | |
| Ko et al. | Jingyue Qiu1, Dandan Sheng1, Fei Lin2, 3*, Peng Jiang4 and Ning Shi1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20160519 |